drugset
drugset / Trial / NCT03730142

A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

NCT03730142 ↗

Phase 1 Completed 82 enrolled Shanghai Jiatan Pharmatech Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory effects on multiple human tumor xenografts. The first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of WX390 at single dose and multiple doses.

Timeline

Start
2018-10-25
Primary completion
2020-07-25
Completion
2020-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject WX390 Unknown 0.1 mg Oral
Subject WX390 Unknown 0.2 mg Oral
Subject WX390 Unknown 0.4 mg Oral
Subject WX390 Unknown 0.7 mg Oral
Subject WX390 Unknown 1.1 mg Oral
Subject WX390 Unknown 1.4 mg Oral
Subject WX390 Unknown 1.7 mg Oral

Indications

No indication recorded.